Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
New data from the U.S. Bureau of Labor Statistics reveals major pay gaps across industries as we head into 2025. While top roles in finance, tech, and healthcare exceed $130,000 to $160,000 a year, other professions lag far behind—even when education levels are similar. Job titles, location, experience, and specialized skills are now some of the biggest factors shaping how much you earn. If you’ve been wondering whether your paycheck is keeping up with the market, this breakdown shows exactly where you stand and what it takes to boost your earning power.
A cooling housing market is giving buyers something they haven’t had in years: room to breathe. With slower sales, more inventory, and less pressure to make snap decisions, homebuyer regret has noticeably declined in 2025. Buyers are feeling more confident thanks to fewer bidding wars, reduced overpaying, and stronger financial preparation—though maintenance surprises still pose challenges. This shift toward a true buyer’s market offers real estate professionals a prime opportunity to guide clients with clarity and confidence.
This week’s commercial real estate roundup unpacks the lingering economic fallout from the 43‑day federal shutdown, new pressures on major office markets, and the rise of STEM‑driven cities reshaping demand nationwide. With fresh Q3 data from Altus showing stronger‑than‑expected transaction momentum, plus updates on Chicago’s valuation slide and national mortgage policy debates, this edition delivers the essential trends CRE, mortgage, finance, and appraisal professionals need to stay ahead.
ATTOM has been named Inman’s 2025 Best of Proptech winner, earning top recognition for its leadership in data and intelligence platforms. With advancements like Snowflake integration, ATTOM Nexus, and enhanced parcel‑centric analytics, the company is shaping the future of AI‑driven real estate decision‑making. This win highlights ATTOM’s growing role as a trusted data backbone for real estate, mortgage, insurance, and investment professionals nationwide.
A new report reveals that Florida’s property insurance market is far from recovering. Despite political claims of stabilization, homeowners are seeing premiums up 54% since 2019, widespread insurer instability, and some companies re‑entering the market under rebranded identities. With high rates of unpaid claims, delayed payouts, and policy non‑renewals, lawmakers are now pushing for transparency and oversight. For homeowners and industry professionals alike, understanding these risks is critical as Florida’s insurance challenges continue to deepen.
Despite new insurers entering the state and lawmakers touting market improvements, a new report reveals Florida’s property insurance system is still plagued by high premiums, weak oversight, and companies with troubled histories. Rates have climbed 54% since 2019, nearly one‑fifth of homeowners are now uninsured, and Florida leads the nation in unpaid and delayed claims. Critics warn that the state’s strategy of shifting risk to undercapitalized private companies may set the stage for another crisis — leaving homeowners, buyers, and real estate professionals navigating a market that’s far from stable.
